Connect with us

Biotech

Qmenta: $10 Million Round Backed by U.S. Investors

Qmenta needs $10 million to further expand. For the time being, the company’s main front will remain neurological diseases. Currently, one billion people worldwide suffer from some kind of neurological disease, and many of the causes and mechanisms are unknown. In fact, nine out of ten drugs aimed at these diseases do not reach the market, generating average costs of $2.6 billion per drug.

Published

on

Qmenta is looking for liquidity to expand its horizons. The Spanish company has opened a $10 million financing round in which it has already brought in several U.S. investors, according to Ernest Figueras, the company’s CFO, as explained to PlantaDoce. The identity of these investors has not been disclosed.

With this capital increase, Qmenta aims to strengthen its business area focused on the field of clinical trials, explore options within the big data business and carry out an expansion process in fields such as radiology and clinical research. By 2021, the company estimates to have generated profits of two million euros.

The company’s technology is based on image recognition using Artificial Intelligence (AI), and aims to accelerate diagnosis and bring drugs to market. Qmenta’s patented AI system enables quantification and sharing of medical images, and although the company is currently heavily focused on the brain, it also aims to strengthen its offering in other medical fields.

If you want to find more details about Qmenta and to read the latest business news in the world, download for free our companion app Born2Invest. Available for both Android and iOS devices, the Born2Invest mobile app keeps its readers up to date with the latest market updates.

Qmenta expects to generate profits of $2.27 million (€2 million) in 2021

For the time being, the company’s main front will remain neurological diseases. Currently, one billion people worldwide suffer from some kind of neurological disease, and many of the causes and mechanisms are unknown. In fact, nine out of ten drugs aimed at these diseases do not reach the market, generating average costs of $2.6 billion per drug.

SEE ALSO  7 neighborhood features to check before buying a home

In this sense, and to minimize the risk of losses, the company aims to provide support so that “the players in the sector can make better decisions,” explained Orlando Marín, head of commercial operations at Qmenta.

The company offers four types of service, including: clinical trials, where it has the Spanish company Icon as a client; research, collaborating with different universities around the world; hospitals and data companies.

Qmenta has more than fifty standard biomarker tools

In fact, the company currently has more than fifty standard biomarker tools and has more than ten million brain images labeled and managed.

On the other hand, Qmenta is present on two continents through its offices in Spain and the United States. The Barcelona headquarters is responsible for managing the market in Europe, the Middle East, and Africa, while in Boston it works with customers in North America and Latin America.

At the end of 2019, the company closed an investment round of more than $1.13 million (€1 million) that aimed to commercialize two of its image analysis algorithms in the United States. Following that transaction, the U.S. Food and Drug Administration (FDA) certified the company to operate in U.S. hospitals.

__

(Featured Image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.